The Breakthrough Treatment for Hypertrophic Cardiomyopathy (HCM) in Cats

Petvital® Rapamycin (Sirolimus) Delayed-release Tablets for Cats

Order Now  for $78/month

Rapamycin (Sirolimus) is a newly FDA conditionally approved for hypertrophic cardiomyopathy (HCM) in cats. By slowing the progression of heart changes,
Rapamycin (Sirolimus) brings hope to cats suffering from HCM.

Rapamycin illustration

Rapamycin (Sirolimus) — Targeted HCM Therapy

Clinical studies show Rapamycin reduces pathological left ventricular thickening and supports cardiac function in cats with hypertrophic cardiomyopathy (HCM).

✓

Slows HCM progression

Reduces abnormal left ventricular thickening and slows mid-stage progression.

✓

Improves quality of life

Alleviates symptoms like breathlessness and fatigue to help cats stay active.

✓

Molecular, targeted action

Inhibits the mTOR pathway to reduce pathological cardiac hypertrophy.

Learn more
About PetVital

Factory-Direct Pet Care

PetVital is a factory-direct supplier for pet owners, dedicated to providing high-quality and affordable pet medications. With 50 years of experience in animal pharmaceutical production and operations, we partner with more than 60 leading European brands and operate GMP-certified production facilities compliant with EU standards. Through our factory-direct model, we reduce unnecessary costs and make sure every pet in need can receive timely treatment.

50+
Years of experience
60+
European brand partners
16+
Research Institutes
Factory-Direct
Lower cost & timely care

Petvital® Rapamycin (Sirolimus) Delayed-release
Tablets for Cats

Order Now
Results Of The RAPACAT Trial

How Rapamycin Was Proven Effective in Cats with HCM

  • Over a 6-month follow-up, untreated cats with subclinical HCM developed significant thickening of the left ventricle.
  • Cats with higher levels of NTproBNP, a blood marker of heart disease, showed faster progression of this thickening.
  • Intermittent inhibition of mTOR with rapamycin successfully prevented the progression of left ventricular hypertrophy.
Research Paper >